PLUS1
2.15
0.10 (4.88%)
0.10 (4.88%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Akers Biosciences Inc | AKER | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.10 | 4.88% | 2.15 | 00:00:01 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 2.15 | 2.08 | 2.21 | 2.09 | 2.05 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 2.10 | 2.27 | 0.17 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 851 | 234,358 | $ 2.14 | $ 502,454 | 1,431,109 | 0.2601 - 8.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:42:29 | 50 | $ 2.13 | USD |
Akers Biosciences Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 18.76M | 8.72M | 8.72M | $ 1.58M | $ - | -6.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Akers Biosciences News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/11/2020 | 18:29 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/11/2020 | 18:27 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/11/2020 | 18:25 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/11/2020 | 18:22 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/11/2020 | 17:17 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 9/09/2020 | 16:56 | Edgar (US Regulatory) | Securities Registration (section 12(b)) (8-a12b) |
| 9/08/2020 | 17:31 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKER Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.41 | 2.65 | 1.97 | 2.38 | 591,858 | -0.26 | -10.79% |
| 1 Month | 2.73 | 2.91 | 1.97 | 2.43 | 1,087,935 | -0.58 | -21.25% |
| 3 Months | 3.53 | 6.97 | 1.97 | 4.19 | 1,302,561 | -1.38 | -39.09% |
| 6 Months | 2.45 | 8.85 | 1.83 | 4.38 | 1,866,675 | -0.30 | -12.24% |
| 1 Year | 0.4802 | 8.85 | 0.2601 | 4.17 | 1,065,079 | 1.67 | 347.73% |
| 3 Years | 0.90 | 8.85 | 0.122 | 0.9482714 | 2,976,069 | 1.25 | 138.89% |
| 5 Years | 3.1701 | 8.85 | 0.122 | 0.964683 | 1,823,275 | -1.02 | -32.18% |
Akers Biosciences Description
| Akers Biosciences Inc is engaged in developing, manufacturing and supplying rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner. The pipeline products of the company focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious disease detection. The majority of the company's revenue comes from the United States. |
